Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2006

View Archived Issues

Novel pathway involved in ADPKD identified / News in Context

New class of PG transporter inhibitors presented

Novel ligand-antibody protein specifically enhances cell lysis in MM

ViroPharma licenses right to develop novel therapeutic for CDAD

Zenyth enters licensing agreement with Ludwig Institute for Cancer Research

Oragenics: business plan for 2006

Callisto to study atiprimod in carcinoid cancer patients

Lucentis BLA for wet AMD granted priority review

Medivation updates progress of Dimebon for Alzheimer's and Huntington's disease

FDA accepts Genasense NDA for relapsed or refractory CLL

Invitrogen agreement supports DelSite's development of avian H5 flu nasal vaccine

RK-0202 set to enter phase III for oral mucositis

Treatment begins in phase III study of Delcath system

Pfizer acquires sanofi-aventis' rights to Exubera

Enzo cleared to begin HIV study of Stealth Vector HGTV43 gene construct

Albany Molecular Research completes acquisition of ComGenex

Astellas acquires Dynogen research facility

Novel compounds claimed for therapy of cardiovascular disorders in recent patent literature

Novel agents for treating diabetes and related complications disclosed in recent patents

BLA submission for Cimzia in Crohn's disease

FDA approval for Erbitux in head and neck cancer

sNDA seeks approval of Byetta for use with TZDs

Tygacil recommended for approval in Europe

Alcon withdraws European submission for Retaane

Tetracaine oral gel may be beneficial for relief of mucositis-related pain / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...